197 related articles for article (PubMed ID: 38589406)
1. Stroma-infiltrating T cell spatiotypes define immunotherapy outcomes in adolescent and young adult patients with melanoma.
Bai X; Attrill GH; Gide TN; Ferguson PM; Nahar KJ; Shang P; Vergara IA; Palendira U; da Silva IP; Carlino MS; Menzies AM; Long GV; Scolyer RA; Wilmott JS; Quek C
Nat Commun; 2024 Apr; 15(1):3014. PubMed ID: 38589406
[TBL] [Abstract][Full Text] [Related]
2. Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma.
Petrova V; Arkhypov I; Weber R; Groth C; Altevogt P; Utikal J; Umansky V
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32235439
[TBL] [Abstract][Full Text] [Related]
3. Immune-Related Toxicity Among Adolescent and Young Adult with Melanoma as Compared with the Elderly.
Darwin A; Skinner A; Reed DR; Tanvetyanon T
J Adolesc Young Adult Oncol; 2022 Dec; 11(6):550-555. PubMed ID: 35100046
[No Abstract] [Full Text] [Related]
4. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.
Genova C; Dellepiane C; Carrega P; Sommariva S; Ferlazzo G; Pronzato P; Gangemi R; Filaci G; Coco S; Croce M
Front Immunol; 2021; 12():799455. PubMed ID: 35069581
[TBL] [Abstract][Full Text] [Related]
5. Tumor Immune Microenvironment Characterization Identifies Prognosis and Immunotherapy-Related Gene Signatures in Melanoma.
Liu D; Yang X; Wu X
Front Immunol; 2021; 12():663495. PubMed ID: 34025664
[TBL] [Abstract][Full Text] [Related]
6. Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma.
Krebs FK; Trzeciak ER; Zimmer S; Özistanbullu D; Mitzel-Rink H; Meissner M; Grabbe S; Loquai C; Tuettenberg A
Cancer Med; 2021 Mar; 10(5):1562-1575. PubMed ID: 33449393
[TBL] [Abstract][Full Text] [Related]
7. Antigen presentation by clonally diverse CXCR5+ B cells to CD4 and CD8 T cells is associated with durable response to immune checkpoint inhibitors.
Ding L; Sun L; Bu MT; Zhang Y; Scott LN; Prins RM; Su MA; Lechner MG; Hugo W
Front Immunol; 2023; 14():1176994. PubMed ID: 37435085
[TBL] [Abstract][Full Text] [Related]
8. Differential responses to immune checkpoint inhibitor dictated by pre-existing differential immune profiles in squamous cell carcinomas caused by same initial oncogenic drivers.
Chen SMY; Popolizio V; Woolaver RA; Ge H; Krinsky AL; John J; Danis E; Ke Y; Kramer Y; Bian L; Nicklawsky AG; Gao D; Liu S; Chen Z; Wang XJ; Wang JH
J Exp Clin Cancer Res; 2022 Apr; 41(1):123. PubMed ID: 35366939
[TBL] [Abstract][Full Text] [Related]
9. Influence of Tumor Immune Infiltration on Immune Checkpoint Inhibitor Therapeutic Efficacy: A Computational Retrospective Study.
Liu R; Yang F; Yin JY; Liu YZ; Zhang W; Zhou HH
Front Immunol; 2021; 12():685370. PubMed ID: 34220837
[TBL] [Abstract][Full Text] [Related]
10. The microbial metabolite desaminotyrosine enhances T-cell priming and cancer immunotherapy with immune checkpoint inhibitors.
Joachim L; Göttert S; Sax A; Steiger K; Neuhaus K; Heinrich P; Fan K; Orberg ET; Kleigrewe K; Ruland J; Bassermann F; Herr W; Posch C; Heidegger S; Poeck H
EBioMedicine; 2023 Nov; 97():104834. PubMed ID: 37865045
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: A multiplex immunohistochemistry-based single-cell analysis.
Isomoto K; Haratani K; Tsujikawa T; Makutani Y; Kawakami H; Takeda M; Yonesaka K; Tanaka K; Iwasa T; Hayashi H; Ito A; Nishio K; Nakagawa K
Lung Cancer; 2022 Dec; 174():71-82. PubMed ID: 36347190
[TBL] [Abstract][Full Text] [Related]
12. Combined Assessment of the Tumor-Stroma Ratio and Tumor Immune Cell Infiltrate for Immune Checkpoint Inhibitor Therapy Response Prediction in Colon Cancer.
Ravensbergen CJ; Polack M; Roelands J; Crobach S; Putter H; Gelderblom H; Tollenaar RAEM; Mesker WE
Cells; 2021 Oct; 10(11):. PubMed ID: 34831157
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppressive capacity of circulating MDSC predicts response to immune checkpoint inhibitors in melanoma patients.
Petrova V; Groth C; Bitsch R; Arkhypov I; Simon SCS; Hetjens S; Müller V; Utikal J; Umansky V
Front Immunol; 2023; 14():1065767. PubMed ID: 36860876
[TBL] [Abstract][Full Text] [Related]
14. Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice.
Chen JS; Hsieh YC; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142591
[TBL] [Abstract][Full Text] [Related]
15. Genes associated with cellular senescence favor melanoma prognosis by stimulating immune responses in tumor microenvironment.
Liang X; Lin X; Lin Z; Lin W; Peng Z; Wei S
Comput Biol Med; 2023 May; 158():106850. PubMed ID: 37031510
[TBL] [Abstract][Full Text] [Related]
16. Immunogenomic characterization in gastric cancer identifies microenvironmental and immunotherapeutically relevant gene signatures.
Han X; Lu H; Tang X; Zhao Y; Liu H
Immun Inflamm Dis; 2022 Jan; 10(1):43-59. PubMed ID: 34582114
[TBL] [Abstract][Full Text] [Related]
17. Boiling histotripsy and in-situ CD40 stimulation improve the checkpoint blockade therapy of poorly immunogenic tumors.
Singh MP; Sethuraman SN; Miller C; Malayer J; Ranjan A
Theranostics; 2021; 11(2):540-554. PubMed ID: 33391491
[No Abstract] [Full Text] [Related]
18. Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review.
Ouwerkerk W; van den Berg M; van der Niet S; Limpens J; Luiten RM
Melanoma Res; 2019 Oct; 29(5):453-464. PubMed ID: 30855527
[TBL] [Abstract][Full Text] [Related]
19. Tumor-infiltrating lymphocyte enrichment predicted by CT radiomics analysis is associated with clinical outcomes of non-small cell lung cancer patients receiving immune checkpoint inhibitors.
Park C; Jeong DY; Choi Y; Oh YJ; Kim J; Ryu J; Paeng K; Lee SH; Ock CY; Lee HY
Front Immunol; 2022; 13():1038089. PubMed ID: 36660547
[TBL] [Abstract][Full Text] [Related]
20. Resistance to immune checkpoint inhibitors and the tumor microenvironment.
Kawashima S; Togashi Y
Exp Dermatol; 2023 Mar; 32(3):240-249. PubMed ID: 36437644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
